ABP215 vs. Bevacizumab in NSCLC (#527)
Laufzeit: 01.01.2014 - 31.12.2015
imported
Kurzfassung
A randomized, double-blind, phase III study evaluating the efficacy and safety of ABP 215 compared with Bevacizumab in subjects with advanced non-small cell lung cancer
